Skip to content
ABOUT
HISTORY
2007
- Merial received conditional USDA approval of canine melanoma vaccine
- AnGes MG stopped Phase 3 angiogenesis trial early upon meeting statistical significance
- Sanofi-aventis initiated Phase 3 angiogenesis trial
- Initiated Phase 1 trial of pandemic influenza vaccine
2006
- Initiated high-dose Allovectin-7® Phase 3 registration trial for metastatic melanoma
- CMV vaccine Phase 2 trial opened for hematopoietic stem cell transplant donors and recipients
- Demonstrated 100% protection in ferrets against H5N1 influenza with single vaccination
2005
- Aqua Health (Novartis) vaccine for salmon received approval in Canada
- Established angiogenesis collaboration with AnGes MG
- Merck advanced in cancer vaccine program
- Exercised and expanded cancer vaccine options
- Initiated cancer vaccine Phase 1 trial
- Initiated IL-2/electroporation Phase 1 trial
- Completed Special Protocol Assessment of Phase 3 pivotal trial for Allovectin-7®
- Completed registered direct placement of stock with net proceeds of $21 million
2004
- Conducted Phase 1 testing of bivalent and trivalent CMV vaccine candidates
- Advanced to Phase 1 testing with anthrax vaccine at NIH-funded sites
- Completed registered direct placement of stock with net proceeds of $17+ million
- Generated record revenues of $14.5 million
2003
- Launched independent vaccine development program for cytomegalovirus, or CMV
- Launched independent vaccine development program for anthrax
- Moved to new facility to consolidate operations and upgrade manufacturing capacity
- Entered agreement with Vaccine Research Center of NIH for bulk DNA vaccine manufacturing
2002
- Issuance of broad patent covering methods for the non-viral, gene-based delivery of physiologically active polypeptides or proteins
- Received STTR grant from NIAID to collaborate with Ohio State University on a preclinical research project to develop DNA vaccines against anthrax.
- Awarded manufacturing contract for clinical-grade supplies of an experimental DNA vaccine against Ebola for initial clinical development by Vaccine Research Center of NIH
- Merial exercised options for specific animal health vaccine indications
- Centocor expanded cancer vaccine license agreement with Vical
2001
- Issuance of key naked DNA patent covering induction of an immune response by administration of naked DNA to any tissue
- Issuance of University of Michigan patent, licensed to Vical, for direct injection of genetic material into tumors or surrounding tissue using viral, lipid-based or other non-viral gene delivery compositions
- Gained access to enhancing technologies including poloxamer technology (CytRx) and electroporation technology (Ichor)
- Appointed prestigious Scientific Advisory Board
- Merck initiated human testing of a prime-boost vaccine regimen employing Vical's DNA technology
2000
- Follow-on offering in January of 3,000,000 shares at $36.50
- Entered strategic partnership with Human Genome Sciences
1999
- Pfizer licensed gene delivery technology for animal health applications
- Merck initiated naked DNA HIV vaccine trial
- Merial selected initial targets for animal health naked DNA vaccines
1998
- Patent issued for lipid-mediated DNA delivery
- Centocor licensed naked DNA for cancer vaccines
- Allovectin-7® entered Phase III registration trials for melanoma
- Leuvectin® entered Phase II trials for kidney cancer
1997
- Additional patents issued for naked DNA applications
- Allovectin-7® started Phase II trial for head and neck cancer
- Leuvectin® started Phase I trial for prostate cancer
- Aventis Pasteur started Phase I malaria vaccine trial
- Aventis Pharma licensed naked DNA to treat neurodegenerative diseases
- Merck licensed naked DNA for therapeutic vaccines against infectious diseases
1996
- Merck started Phase I trial with DNA vaccine to prevent influenza
- Collaboration with Stanford on Vaxid DNA vaccines for B-cell lymphoma
- First patent issued from 1989 filing on naked DNA technology
1995
- Allovectin-7® entered Phase II clinical trials
- Leuvectin® entered Phase I clinical trials
- Merial licensed DNA vaccines for veterinary applications
- Follow-on offering in September of 2,500,000 shares at $12.25
1994
- Allovectin-7® entered Phase I clinical trials
- Merck expanded naked DNA infectious disease vaccine license
- Aventis Pasteur licensed naked DNA for infectious disease vaccines
1993
- Initial public offering in March of 2,000,000 shares at $5.00
- Follow-on offering in July of 2,000,000 shares at $7.00
1991
- Merck licensed naked DNA for infectious disease vaccines
1989
- Discovered naked DNA and filed patent applications
1987
- Incorporated in April to research & develop proprietary lipid chemistry